BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $16.13.

A number of analysts recently weighed in on BCRX shares. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 target price on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Xponance Inc. grew its position in BioCryst Pharmaceuticals by 9.1% during the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 1,242 shares during the last quarter. Sei Investments Co. boosted its stake in shares of BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock valued at $430,000 after purchasing an additional 1,537 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 2,146 shares during the last quarter. Mariner LLC raised its position in BioCryst Pharmaceuticals by 32.1% in the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,224 shares during the period. Finally, Arizona State Retirement System lifted its stake in BioCryst Pharmaceuticals by 6.6% in the fourth quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company’s stock worth $429,000 after purchasing an additional 3,518 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $8.93 on Friday. The firm has a market capitalization of $1.87 billion, a P/E ratio of -14.64 and a beta of 1.08. BioCryst Pharmaceuticals has a one year low of $4.42 and a one year high of $9.50. The business has a fifty day moving average price of $7.69 and a 200-day moving average price of $7.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the company posted $0.28 EPS. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. Sell-side analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.